| Literature DB >> 23507195 |
Namiko Okuyama1, Wolfgang R Sperr, Katalin Kadar, Sietske Bakker, Gergely Szombath, Hiroshi Handa, Hideto Tamura, Asaka Kondo, Peter Valent, Judit Várkonyi, Arjan van de Loosdrecht, Kiyoyuki Ogata.
Abstract
Myelodysplastic syndromes (MDS) often transform into acute leukemia (AL-MDS), although its prognostic details have not been examined thoroughly. We retrospectively analyzed the prognosis of 189 AL-MDS patients. Ninety-four patients received best supportive care (BSC), and 94 patients received disease-modifying therapies (DMT) that included chemotherapy (CHT) for 65 patients, allogeneic stem-cell transplantation (allo-SCT) for 21 patients, and other therapies for 8 patients. The median survival time was 142 days. In patients treated with BSC, platelet count alone was an independent prognostic factor. In younger patients treated with DMT (<60 years, N=25), allo-SCT was an independent prognostic factor associated with longer survival. In older patients treated with DMT (≥60 years, N=69), the therapy type did not affect survival, and performance status and MDS-specific comorbidity index were independent prognostic factors.Entities:
Mesh：
Year: 2013 PMID： 23507195 DOI： 10.1016/j.leukres.2013.02.018
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156